Statera BioPharma Profit Margin

Statera BioPharma posts a profit margin of -28.29% as of September 2022. That compares with -61.78% in the prior-year period — up 54.2% year over year. That is below the Healthcare sector average of 15.52%. Comparing that reading with peers and prior periods is usually more useful than looking at the number in isolation.

In the prior comparable period, Statera BioPharma's profit margin was -61.78%. The latest reading is -28.29% — a 54.2% year-over-year increase (period ending September 2022). Use the history and growth charts on this page for a longer lookback.

For Healthcare stocks, a profit margin near 15.52% is typical. Statera BioPharma's -28.29% is lower that level. That is roughly 18330.2% below the sector mean. Whether that is a warning or an opportunity depends on growth outlook and other fundamentals shown elsewhere on Stockcircle.

Statera BioPharma's profit margin moves when the underlying profit, equity, or asset base changes. Cost cuts, pricing power, buybacks, write-downs, and cyclical swings can all shift the percentage. The latest reading is -28.29% as of September 2022; use YoY and peer views to separate noise from signal.

Context for STAB's profit margin usually means three checks: (1) trend versus prior periods, (2) level versus peers (average 15.52%), and (3) consistency with growth and profitability. This page covers the first two; Statera BioPharma's other metric pages and overview cover the third.